Daiichi Sankyo and Merck enter into global agreement for MK-6070

To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights

Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH

Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)

Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection

Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

Hyperfine bringing Swoop to India through distribution partnership with Radiosurgery Global

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market

FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients

Merck to showcase advances in the science of cancer with new data presented at ASCO 2024

Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors

Cipla receives final approval for the generic version of Somatuline Depot Injection

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India